Phase I Study of Oral S-1 Plus Cisplatin With Concurrent Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer

Article ID	Journal	Published Year	Pages	File Type
8234801	International Journal of Radiation OncologyBiologyPhysics	2009	6 Pages	PDF

Abstract

The RD is the level 0 dose, and this regimen is a feasible and well-tolerated regimen for the treatment of patients with Stage III NSCLC.

Keywords

S-1 Non–small-cell lung cancer cisplatin Chemoradiotherapy Phase I study Concurrent

Related Topics

Physical Sciences and Engineering Physics and Astronomy Radiation

Preview

Phase I Study of Oral S-1 Plus Cisplatin With Concurrent Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer

Authors

Kyoichi M.D., Ph.D., Noriaki M.D., Ph.D., Noriko M.D., Ph.D., Tadayoshi M.D., Ph.D., Mitsuyoshi M.D., Ph.D., Kimihiro M.D., Ph.D., Takeshi M.D., Ph.D., Hidemasa M.D., Tetsuo M.D., Ph.D., Hitoshi M.D., Ph.D., Hideyuki M.D., Ph.D., Tatsuo M.D., Ph.D.,